Member access

4-Traders Homepage  >  Shares  >  Nasdaq  >  Alnylam Pharmaceuticals, Inc.    ALNY   US02043Q1076

 SummaryQuotesChart AnalysisNewsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
10/13/2014 10/14/2014 10/15/2014 10/16/2014 10/17/2014 Date
86.68(c) 82.95(c) 84.39(c) 84.94(c) 86.18(c) Last
3 665 263 1 330 488 1 452 950 871 958 1 458 014 Volume
+18.98% -4.30% +1.74% +0.65% +1.46% Change
More quotes
Company
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company, which develops novel therapeutics based on RNA interference.It is leading the translation of RNAi as a new class of innovative medicines with a core focus on RNAi therapeutics for the treatment of genetically defined diseases, including... 
Surperformance© rating of Alnylam Pharmaceuticals, I
Trading Rating : Investor Rating :
More about the company
Chart ALNYLAM PHARMACEUTICALS, I
Duration : Period :
Alnylam Pharmaceuticals, I Technical Analysis Chart | ALNY | US02043Q1076 | 4-Traders
Full-screen chart
Financials ($)
Sales 2014 33,6 M
EBIT 2014 -332 M
Net income 2014 -341 M
Finance 2014 737 M
Yield 2014 -
Sales 2015 50,8 M
EBIT 2015 -199 M
Net income 2015 -210 M
Finance 2015 698 M
Yield 2015 -
PER 2014 -
PER 2015
EV / Sales 2014 174x
EV / Sales 2015 116x
Capitalization 6 580 M
More Financials
Latest news on ALNYLAM PHARMACEUTICALS, I
4d ago ALNYLAM PHARMACEUTICALS : Posts Patisiran Study Data
6d ago ALNYLAM PHARMACEUTICALS : Presents New Clinical and Pre-Clinical Data on RNAi Th..
7d ago ALNYLAM PHARMACEUTICALS : Reports Six-Month Clinical Data from Patisiran Phase 2..
10/08 ALNYLAM PHARMACEUTICALS : Initiates EXPLORE, a Prospective Observational Study o..
10/03 ALNYLAM PHARMACEUTICALS : Initiates DISCOVERY, a Screening Study Examining the P..
10/01 ALNYLAM PHARMACEUTICALS : Initiates EXPLORE, a Prospective Observational Study o..
09/29 ALNYLAM PHARMACEUTICALS : Commences Discovery Trial
09/26 ALNYLAM PHARMACEUTICALS : Submission of Matters to a Vote of Security Holders (f..
09/24 ALNYLAM PHARMACEUTICALS : Presents New Pre-Clinical Data with ALN-CC5, a Subcuta..
09/24 Alnylam Strengthens Management Team with New Key Appointments
09/24 ALNYLAM PHARMACEUTICALS : Broadens Pipeline with ALN-AGT, a Subcutaneously Admin..
09/24 ALNYLAM PHARMACEUTICALS : to Webcast Presentation at Leerink Partners Rare Disea..
More news


Comments 
Advertisement
Technical analysis trends
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Technical analysis
Income Statement Evolution
More Financials
EPS Revisions
More Estimates Revisions
Dynamic quotes  
ON
| OFF